The Relationship Between IMP3 Expression in Colorectal Adenocarcinoma and Clinicopathologic Findings

The Relationship Between IMP3 Expression in Colorectal Adenocarcinoma and Clinicopathologic Findings


Fatemeh Radfar 1
,
Farzad Achak 2
and
Farzad Rajaei 1 , 3 , *

Authors Information

1 Department of Anatomy, Qazvin University of Medical Sciences, Qazvin, IR Iran
2 Department of Pathology, Alborz University of Medical Sciences, Karaj, IR Iran
3 Cellular and Molecular Research Centre, Qazvin University of Medical Sciences, Qazvin, IR Iran
Article information
  • Biotechnology and Health Sciences: August 01, 2015, 2 (3); e27414
  • Published Online: August 24, 2015
  • Article Type: Research Article
  • Received: January 27, 2015
  • Revised: June 23, 2015
  • Accepted: July 1, 2015
  • DOI: 10.17795/bhs27414

To Cite: Radfar F, Achak F, Rajaei F. The Relationship Between IMP3 Expression in Colorectal Adenocarcinoma and Clinicopathologic Findings, Biotech Health Sci. 2015 ;2(3):e27414. doi: 10.17795/bhs27414.

Abstract
Copyright: Copyright © 0, Biotechnology and Health Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Mueller-Pillasch F, Pohl B, Wilda M, Lacher U, Beil M, Wallrapp C, et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev. 1999; 88(1): 95-9[PubMed]
  • 2. Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol. 1999; 19(2): 1262-70[PubMed]
  • 3. Findeis-Hosey JJ, Xu H. The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology. Hum Pathol. 2011; 42(3): 303-14[DOI][PubMed]
  • 4. Schaeffer DF, Owen DR, Lim HJ, Buczkowski AK, Chung SW, Scudamore CH, et al. Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. BMC Cancer. 2010; 10: 59[DOI][PubMed]
  • 5. Yantiss RK, Woda BA, Fanger GR, Kalos M, Whalen GF, Tada H, et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol. 2005; 29(2): 188-95[PubMed]
  • 6. Simon R, Bourne PA, Yang Q, Spaulding BO, di Sant’Agnese PA, Wang HL, et al. Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not. Hum Pathol. 2007; 38(8): 1178-83[DOI][PubMed]
  • 7. Sojka KM, Spaulding BS, Nielsen GK, Dinnogen SA, Welcher R. Immunoreactivity of anti-L523S on normal and malignant lung pleural tissue biopsies. Mod Pathol. 2006; 18: 288
  • 8. Xu H, Bourne PA, Spaulding BO, Wang HL. High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum Pathol. 2007; 38(4): 555-63[DOI][PubMed]
  • 9. Jiang Z, Chu PG, Woda BA, Liu Q, Balaji KC, Rock KL, et al. Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas. Clin Cancer Res. 2008; 14(17): 5579-84[DOI][PubMed]
  • 10. Jiang Z, Chu PG, Woda BA, Rock KL, Liu Q, Hsieh CC, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol. 2006; 7(7): 556-64[DOI][PubMed]
  • 11. Hoffmann NE, Sheinin Y, Lohse CM, Parker AS, Leibovich BC, Jiang Z, et al. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer. 2008; 112(7): 1471-9[DOI][PubMed]
  • 12. Pryor JG, Bourne PA, Yang Q, Spaulding BO, Scott GA, Xu H. IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol. 2008; 21(4): 431-7[DOI][PubMed]
  • 13. Jeng YM, Wang TH, Lu SH, Yuan RH, Hsu HC. Prognostic significance of insulin-like growth factor II mRNA-binding protein 3 expression in gastric adenocarcinoma. Br J Surg. 2009; 96(1): 66-73[DOI][PubMed]
  • 14. Gu L, Shigemasa K, Ohama K. Increased expression of IGF II mRNA-binding protein 1 mRNA is associated with an advanced clinical stage and poor prognosis in patients with ovarian cancer. Int J Oncol. 2004; 24(3): 671-8[PubMed]
  • 15. Kobel M, Xu H, Bourne PA, Spaulding BO, Shih Ie M, Mao TL, et al. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol. 2009; 22(3): 469-75[DOI][PubMed]
  • 16. Sitnikova L, Mendese G, Liu Q, Woda BA, Lu D, Dresser K, et al. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res. 2008; 14(6): 1701-6[DOI][PubMed]
  • 17. Mhawech-Fauceglia P, Herrmann FR, Rai H, Tchabo N, Lele S, Izevbaye I, et al. IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. Am J Clin Pathol. 2010; 133(6): 899-908[DOI][PubMed]
  • 18. Lu D, Yang X, Jiang NY, Woda BA, Liu Q, Dresser K, et al. IMP3, a new biomarker to predict progression of cervical intraepithelial neoplasia into invasive cancer. Am J Surg Pathol. 2011; 35(11): 1638-45[DOI][PubMed]
  • 19. Hammer NA, Hansen T, Byskov AG, Rajpert-De Meyts E, Grondahl ML, Bredkjaer HE, et al. Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer. Reproduction. 2005; 130(2): 203-12[DOI][PubMed]
  • 20. Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL, Khan A. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Hum Pathol. 2009; 40(11): 1528-33[DOI][PubMed]
  • 21. Chen ST, Jeng YM, Chang CC, Chang HH, Huang MC, Juan HF, et al. Insulin-like growth factor II mRNA-binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma. Cancer Sci. 2011; 102(12): 2191-8[DOI][PubMed]
  • 22. Lochhead P, Imamura Y, Morikawa T, Kuchiba A, Yamauchi M, Liao X, et al. Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Eur J Cancer. 2012; 48(18): 3405-13[DOI][PubMed]
  • 23. Lin L, Zhang J, Wang Y, Ju W, Ma Y, Li L, et al. Insulin-like growth factor-II mRNA-binding protein 3 predicts a poor prognosis for colorectal adenocarcinoma. Oncol Lett. 2013; 6(3): 740-4[DOI][PubMed]
  • 24. Li D, Yan D, Tang H, Zhou C, Fan J, Li S, et al. IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol. 2009; 16(12): 3499-506[DOI][PubMed]
  • 25. Yuan RH, Wang CC, Chou CC, Chang KJ, Lee PH, Jeng YM. Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma. Ann Surg Oncol. 2009; 16(6): 1711-9[DOI][PubMed]